You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 9, 2025

Drug Price Trends for NDC 00536-1061


✉ Email this page to a colleague

« Back to Dashboard


Average Pharmacy Cost for 00536-1061

Drug Name NDC Price/Unit ($) Unit Date
BLUE 2% GEL 00536-1061-39 0.01267 GM 2025-01-22
BLUE 2% GEL 00536-1061-39 0.01308 GM 2024-12-18
BLUE 2% GEL 00536-1061-39 0.01309 GM 2024-11-20
BLUE 2% GEL 00536-1061-39 0.01344 GM 2024-10-23
BLUE 2% GEL 00536-1061-39 0.01394 GM 2024-09-18
BLUE 2% GEL 00536-1061-39 0.01350 GM 2024-08-21
BLUE 2% GEL 00536-1061-39 0.01373 GM 2024-07-17
>Drug Name >NDC >Price/Unit ($) >Unit >Date

Best Wholesale Price for NDC 00536-1061

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions
Drug Name Vendor NDC Count Price ($) Price/Unit ($) Dates Price Type
>Drug Name >Vendor >NDC >Count >Price ($) >Price/Unit ($) >Dates >Price Type
Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Market Analysis and Price Projections for the Pharmaceutical Industry: Implications for NDC 00536-1061

Introduction

The pharmaceutical industry is a complex and dynamic sector, influenced by various factors including regulatory changes, technological advancements, and market demand. This analysis will delve into the broader market trends and price projections that could impact a specific drug identified by its National Drug Code (NDC), in this case, NDC 00536-1061.

Understanding the National Drug Code (NDC)

The NDC is a unique, three-segment number that identifies the labeler, product, and trade package size of a drug product. It is a critical identifier used across the healthcare industry for billing, inventory, and clinical practices[1][5].

Global Pharmaceutical Market Trends

The global pharmaceutical market is expected to experience robust growth driven by several factors:

Ageing Populations and Emerging Markets

Global pharmaceutical output is forecast to increase by 3% in 2024, 4% in 2025, and 3.6% in 2026. Regions such as Asia Pacific and the Middle East are expected to have the largest annual growth rates. The demand for medications, especially those targeting chronic conditions, is anticipated to rise significantly among ageing populations[3].

Specialty Pharmaceuticals

Specialty pharmaceuticals, which include drugs for complex or chronic conditions like cancer, infectious diseases, and autoimmune disorders, are a significant driver of market growth. These drugs are expected to see a price increase of 4.18% in the coming year, with weight loss drugs and gene therapies being notable contributors[2].

Price Projections and Market Drivers

Several factors are influencing the price projections in the pharmaceutical market:

Weight Loss Drugs

The utilization of weight loss drugs, such as GLP-1 agonists like semaglutide and tirzepatide, has seen a dramatic increase. These drugs are expected to continue driving spending and market growth, with the weight loss medication market projected to reach USD 80 billion by 2030[2][3].

Gene Therapies

Gene therapies, though expensive, are gaining traction. A single dose can exceed $2 million, and with over 170 gene and cellular therapies in the pipeline, these treatments are expected to significantly impact disease prevention and treatment. However, their high cost and specific storage requirements pose challenges[2].

Biosimilars

Biosimilars are expected to grow in market share, particularly as pharmacy benefit managers finalize their formulary strategies. While biosimilars offer cost savings, they also face challenges such as pricing and reimbursement coding[2].

Specific Market Analysis for NDC 00536-1061

To provide a detailed analysis for a specific NDC like 00536-1061, we need to identify the drug it corresponds to and its therapeutic category.

Identifying the Drug

Without specific information on the drug associated with NDC 00536-1061, we can infer general trends based on the broader market analysis.

Therapeutic Category

If the drug falls under a category like specialty pharmaceuticals (e.g., oncology, autoimmune diseases), it is likely to be influenced by the trends mentioned above. For instance, if it is an oncology drug, it might be part of the non-small cell lung cancer (NSCLC) market, which is expected to see significant growth driven by immunotherapies and targeted therapies[4].

Price Projections

Given the general trends:

  • Specialty Pharmaceuticals: If NDC 00536-1061 corresponds to a specialty pharmaceutical, it could see a price increase similar to the projected 4.18% for specialty medications. This would be driven by factors such as increasing demand, novel therapies, and regulatory environments[2].
  • Biosimilars and Generics: If the drug has biosimilar or generic alternatives, the price might be influenced by the competition and pricing strategies of these alternatives. Biosimilars, for example, are expected to increase in price by only 0.55%, which could impact the pricing of the original drug[2].

Regulatory and Operational Challenges

The healthcare industry faces several challenges related to drug identifiers like the NDC:

  • Format Consistency: Ensuring the NDC is in a consistent format is crucial to avoid issues such as reimbursement delays and patient safety risks. Any changes to the NDC format, such as transitioning from 10-digit to 11-digit codes, must be carefully managed to avoid confusion and duplication[1].
  • Supply Chain and Reimbursement: The use of NDCs in pharmacy systems and reimbursement processes highlights the importance of accurate and consistent coding. This affects not only the drug's market performance but also its availability and accessibility[1].

Conclusion

The pharmaceutical market is poised for significant growth, driven by factors such as ageing populations, emerging markets, and the development of new therapies. For a specific drug like the one identified by NDC 00536-1061, the price projections would depend on its therapeutic category, the presence of biosimilar or generic alternatives, and broader market trends.

Key Takeaways

  • Global Growth: The global pharmaceutical market is expected to grow by 3% in 2024 and 4% in 2025.
  • Specialty Pharmaceuticals: These drugs, including those for weight loss and gene therapies, are driving significant market growth.
  • Biosimilars: Expected to increase in market share, particularly as formulary strategies are finalized.
  • Regulatory Challenges: Consistency in NDC formatting and management of transitions are critical for patient safety and operational efficiency.
  • Therapeutic Category: The specific category of the drug (e.g., oncology, autoimmune diseases) will influence its price projections.

FAQs

Q: What is the National Drug Code (NDC) and its significance? A: The NDC is a unique, three-segment number that identifies the labeler, product, and trade package size of a drug product. It is crucial for billing, inventory, and clinical practices across the healthcare industry[1][5].

Q: How are specialty pharmaceuticals impacting the market? A: Specialty pharmaceuticals are driving significant market growth, particularly those targeting complex or chronic conditions. They are expected to see a price increase of 4.18% in the coming year[2].

Q: What role do biosimilars play in the pharmaceutical market? A: Biosimilars are expected to grow in market share, offering cost savings compared to branded drugs. However, they face challenges such as pricing and reimbursement coding[2].

Q: How do gene therapies affect the market? A: Gene therapies are expensive but are gaining traction. They are expected to significantly impact disease prevention and treatment, though they pose challenges such as high cost and specific storage requirements[2].

Q: What are the implications of NDC format changes for the healthcare industry? A: Changes to the NDC format must be carefully managed to avoid confusion, duplication, and patient safety risks. A structured national communication plan is recommended to reduce confusion during transitions[1].

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.